. 2022 Jul 7;11(3):1399–1408. doi: 10.1007/s40120-022-00377-1

Table 2.

Analysis of patient characteristics distinguishing success or failure with BIW INFβ1a treatment

	Stable on BIW interferon	Active on BIW interferon	P value
Age at onset of MS, N = 40 mean (SD)	33.9 (12.5)	33.4 (9.6)	0.955
Sex, N = 40
Male (%)	19 (82.6)	12 (70.6)	0.456
Female (%)	4 (17.4)	5 (29.4)	0.456
Race, N = 40
African American (%)	3 (13)	5 (29.4)	0.333
Hispanic (%)	1 (4.3)	0
White (%)	19 (82.6)	12 (70.6)
Duration of disease prior to QW INFβ, N = 40
Mean years (SD)	16 (11.5)	13.7 (10.3)	0.506
Type of MS disease, N = 40
RR (%)	6 (26.1)	7 (41.2)	0.718
SP (%)	17 (73.9)	10 (58.8)
Age at start of QW INFβ, N = 40 mean (SD)	50.3 (10.4)	47.8 (8.7)	0.410
Age at start of BIW INFβ, N = 40 mean (SD)	52.1 (10.4)	49.8 (8.4)	0.457
Duration of disease prior to BIW INFβ, N = 40
Mean years (SD)	17.8 (12)	13.7 (10.3)	0.506
Type of MS disease at start of BIW INFβ, N = 40
RR (%)	5 (21.7)	7 (41.2)	0.715
SP (%)	18 (78.3)	10 (58.8)	0.715
EDSS score at start of QW INFβ, N = 40 mean (SD)	5 (1.6)	5.3 (1.4)	0.575
Number of relapses in the 2 years prior to start of QW INFβ, N = 40
Mean (SD)	1 (1.2)	2.1 (1.6)	0.020
Number of relapses in the 2 years prior to start of BIW INFβ, N = 40
Mean (SD)	1.3 (1.5)	1.9 (1.4)	0.254
EDSS score at start of BIW INFβ, N = 40 mean (SD)	5.3 (1.6)	5.4 (1.4)	0.804
Stable on QW INFβ prior to switch to BIW, N = 40
Yes (%)	5 (21.7)	3 (17.6)	0.999
No (%)	18 (78.3)	14 (82.4)
Duration of QW stability prior to switch to BIW, N = 8
Mean years (SD)	4.2 (3.5)	5.7 (2.1)	0.540
Worsening EDSS as reason for BIW INFβ, N = 40
Yes (%)	9 (39.1)	5 (29.4)	0.763
No (%)	14 (60.9)	12 (70.6)
Worsening neurological exam as reason for BIW INFβ, N = 40
Yes (%)	9 (39.1)	10 (58.8)	0.361
No (%)	14 (60.9)	7 (41.2)	0.361